The Italian pharmaceutical market environment, from regulatory to regulatory, has always been a highly changeable scenario, both because of continuous technological advances and because of regulations that adapt to innovation and chase urgencies.
We live in interesting times, we are experiencing an epoch-making moment, the SARS-CoV-2 pandemic; in Italy, all stakeholders are working - some planning, some lobbying with proposals - on a new drug governance. With this infographic, we have tried to imagine the future scenario of market access in these interesting times.

New simplified P&R negotiation procedures
In 2020, AIFA introduced the new simplified P&R negotiation procedures: simplified price and reimbursement procedure for drug negotiations